Company Performance - Lyra Therapeutics reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.35 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of $0.18 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 23.75%, and a decline from year-ago revenues of $0.53 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times, but has topped consensus revenue estimates only once [2] Stock Performance - Lyra Therapeutics shares have declined approximately 49.7% since the beginning of the year, compared to a decline of 3.9% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $0.24 million, and for the current fiscal year, it is -$0.61 on revenues of $0.97 million [7] Industry Outlook - The Medical - Drugs industry, to which Lyra Therapeutics belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Lyra Therapeutics may be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Core Viewpoint - Redfin reported a quarterly loss of $0.73 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.69, and a decline from a loss of $0.57 per share a year ago, indicating ongoing challenges in the real estate market [1] Financial Performance - The company posted revenues of $221.03 million for the quarter ended March 2025, slightly surpassing the Zacks Consensus Estimate by 0.31%, but down from $225.48 million in the same quarter last year [2] - Over the last four quarters, Redfin has exceeded consensus revenue estimates three times, but has only surpassed EPS estimates once [2] Stock Performance - Redfin shares have increased by approximately 17.2% since the beginning of the year, contrasting with a decline of -3.9% in the S&P 500 [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $295.11 million, and for the current fiscal year, it is -$1.05 on revenues of $1.05 billion [7] - The estimate revisions trend for Redfin is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Real Estate - Operations industry, to which Redfin belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Redfin's stock performance [5]

Company Performance - Aligos Therapeutics reported a quarterly loss of $2.11 per share, which was better than the Zacks Consensus Estimate of a loss of $2.80, and an improvement from a loss of $5.50 per share a year ago, indicating a 24.64% earnings surprise [1] - The company posted revenues of $0.31 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 68.90%, and down from $0.99 million in the same quarter last year [2] - Over the last four quarters, Aligos Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - Aligos Therapeutics shares have declined approximately 87.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$2.74 on $1 million in revenues, and for the current fiscal year, it is -$8.66 on $39.5 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Aligos Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aligos Therapeutics' stock performance [5][6]

Group 1 - Camden National reported quarterly earnings of $0.95 per share, missing the Zacks Consensus Estimate of $0.99 per share, but showing an increase from $0.86 per share a year ago, resulting in an earnings surprise of -4.04% [1] - The company posted revenues of $60.05 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.06%, compared to year-ago revenues of $41.6 million [2] - Camden National has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] Group 2 - The stock has underperformed the market, losing about 7.3% since the beginning of the year, compared to the S&P 500's decline of -3.9% [3] - The current consensus EPS estimate for the coming quarter is $1.08 on revenues of $59.44 million, and for the current fiscal year, it is $4.36 on revenues of $242.86 million [7] - The Zacks Industry Rank for Banks - Northeast is currently in the top 19% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.20 per share, missing the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.04%. A quarter ago, it was expected that this company would post earnings of $1.29 per share when it actually produced earnings of $1.52, delivering a surprise of 17.83%.Over the last four quarters, the c ...

Priority Technology (PRTH) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.18, delivering a surprise of 200%.Over the last four quarters, the company has s ...

Core Insights - Orthofix reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.17, and an improvement from a loss of $0.46 per share a year ago, indicating a 52.94% earnings surprise [1] - The company achieved revenues of $193.65 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.87% and showing a year-over-year increase from $188.61 million [2] - Orthofix shares have declined approximately 22.5% year-to-date, contrasting with the S&P 500's decline of 3.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.08, with projected revenues of $204 million, and for the current fiscal year, the EPS estimate is $0.62 on revenues of $823.9 million [7] - The estimate revisions trend for Orthofix is currently favorable, leading to a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Orthofix belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a strong performance potential [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Axcelis Technologies (ACLS) reported quarterly earnings of $1.04 per share, significantly exceeding the Zacks Consensus Estimate of $0.39 per share, although down from $1.57 per share a year ago, resulting in an earnings surprise of 166.67% [1] - The company achieved revenues of $192.56 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.29%, but down from $252.37 million year-over-year [2] - Axcelis has consistently surpassed consensus EPS estimates over the last four quarters [2] Earnings Outlook - The sustainability of Axcelis' stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.57 on revenues of $193.3 million, and for the current fiscal year, it is $2.39 on revenues of $778.8 million [7] Industry Context - The Electronics - Manufacturing Machinery industry, to which Axcelis belongs, is currently ranked in the bottom 9% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Axcelis' stock performance [5] Stock Performance - Axcelis shares have declined approximately 25.5% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The estimate revisions trend for Axcelis is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6]

Avanos Medical (AVNS) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 36.84%. A quarter ago, it was expected that this medical technology company would post earnings of $0.40 per share when it actually produced earnings of $0.43, delivering a surprise of 7.50%.Over the last four quart ...

Company Performance - TScan Therapeutics reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.28, and an improvement from a loss of $0.32 per share a year ago, representing an earnings surprise of 7.14% [1] - The company posted revenues of $2.17 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 34.43%, compared to revenues of $0.57 million in the same quarter last year [2] - Over the last four quarters, TScan Therapeutics has surpassed consensus EPS estimates three times [2] Stock Performance - TScan Therapeutics shares have declined approximately 50.7% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $1.62 million, and for the current fiscal year, it is -$1.15 on revenues of $10.97 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which TScan Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact TScan's stock performance [5]